Whether belumosudil is a hormonal drug and analysis of its effects

Belumosudil (Belumosudil) is not a hormonal drug, but a selective ROCK2 (Rhorelated coiled-coil-containing protein kinase 2) inhibitor. It is a new type of small molecule targeted drug that mainly achieves immune regulation and anti-inflammatory effects by regulating intracellular signaling pathways. It is completely different from traditional hormonal drugs (such as glucocorticoids) in structure and mechanism of action. Therefore, clinically, besudil provides a new treatment option for patients who cannot use hormones for a long time or who have insufficient hormone efficacy.

The main indication of Besudil is the treatment of chronic graft-versus-host disease (cGVHD), a serious complication after hematopoietic stem cell transplantation that often requires long-term immunosuppressive treatment. Traditionally, hormone drugs such as prednisone are the first-line treatment for cGVHD, but some patients are ineffective or poorly tolerated by hormone therapy. Besudil affects T cell differentiation, inflammatory factor production and tissue fibrosis by inhibiting the ROCK2 signaling pathway, thereby effectively alleviating cGVHD related symptoms, especially in patients who have failed hormone therapy, showing good results.

In terms of pharmacological effects, Besudil not only has immunomodulatory functions, but also inhibits the expression of a variety of inflammatory factors, such as IL-17, IL-21, etc., helping to reduce chronic inflammation and tissue damage. At the same time, it is also being studied as a potential treatment for other immune-related diseases, such as systemic sclerosis, atopic dermatitis, etc. Due to its precise targeting mechanism, Besudil has milder side effects than hormone drugs and does not cause common hormone-related adverse reactions such as osteoporosis, hyperglycemia, water and sodium retention, etc.

In general, besudil, as a non-hormone targeted drug, has filled the gap in the treatment of some immune diseases. It provides new treatment ideas for patients who are ineffective or intolerant to hormone therapy and achieves more precise and sustained immune regulation by targeting the ROCK2 pathway. In the future, with the deepening of research, its indications are expected to be further expanded and it will become one of the standard treatment options for a variety of chronic immune diseases.

Reference materials:https://www.drugs.com/